The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)
Open accessPublished version of a preprint
Abstract
Selumetinib (AZD6244, ARRY-142886) is a selective, non–ATP-competitive inhibitor of mitogen-activated protein/extracellular signal–regulated kinase kinase (MEK)-1/2. The range of antitumor activity seen preclinically and in patients highlights the importance of identifying determinants of response to this drug. In large tumor cell panels of diverse lineage, we show that MEK inhibitor response does not have an absolute correlation with mutational or phospho-protein markers of BRAF/MEK, RAS, or phosphoinositide 3-kinase (PI3K) activity. We aimed to enhance predictivity by measuring pathway output through coregulated gene networks displaying differential mRNA expression exclusive to resistant cell subsets and correlated to mutational or dynamic pathway activity. We discovered an 18-gene signature enabling measurement of MEK functional output independent of tumor genotype. Where the MEK pathway is activated but the cells remain resistant to selumetinib, we identified a 13-gene signature that implicates the existence of compensatory signaling from RAS effectors other than PI3K. The ability of these signatures to stratify samples according to functional activation of MEK and/or selumetinib sensitivity was shown in multiple independent melanoma, colon, breast, and lung tumor cell lines and in xenograft models. Furthermore, we were able to measure these signatures in fixed archival melanoma tumor samples using a single RT-qPCR–based test and found intergene correlations and associations with genetic markers of pathway activity to be preserved. These signatures offer useful tools for the study of MEK biology and clinical application of MEK inhibitors, and the novel approaches taken may benefit other targeted therapies. Cancer Res; 70(6); 2264–73
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It is noteworthy that the 13-gene signature was developed from cell lines treated with the MEKi for a 72 h period [6] during which AR could be induced [11].”
From An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapy (2022) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although RAS/RAF-mutated CRC has been targeted for the development of therapeutic inhibitors, they have been largely ineffective, likely due to complex resistance mechanisms such as intrinsic and adaptive resistance [5–12].”
From An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapy (2022) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, MEK inhibitors, used alone, have been largely ineffective, likely due to intrinsic and adaptive resistance mechanisms [5–7].”
From An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapy (2022) · cites this paper as [6]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gene expression profiling predicts clinical outcome of breast cancer
van 't Veer, L. J., Dai, H., van de Vijver, M. J., He, Y. D., Hart, A. A. M., Mao, M., Peterse, H. L., van der Kooy, K., Marton, M. J., Witteveen, A. T., et al. (2002) · Nature · doi:10.1038/415530a · Cited by 9,536
A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
Paik, S., Shak, S., Tang, G., Kim, C., Baker, J. B., Cronin, M. T., Baehner, F. L., Walker, M. G., Watson, D., Park, T., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041588 · Cited by 6,321
ONCOMINE: A Cancer Microarray Database and Integrated Data-Mining Platform
Rhodes, D. R., Yu, J., Sundaram, S. K., Deshpande, N., Varambally, R., Ghosh, D., Barrette, T. R., Pander, A., & Chinnaiyan, A. M. (2004) · Neoplasia · doi:10.1016/s1476-5586(04)80047-2 · Cited by 3,590
Harris, L. N., Fritsche, H. A., Mennel, R. G., Norton, L., Ravdin, P. M., Taube, S. E., Somerfield, M. R., Hayes, D. F., & Bast, R. C. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.2364 · Cited by 2,234
KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer
Lièvre, A., Bachet, J.-B., Le Corre, D., Boige, V., Landi, B., Emile, J.-F., Côté, J.-F., Tomasic, G., Penna, C., Ducreux, M., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0191 · Cited by 2,229
Oncogenic pathway signatures in human cancers as a guide to targeted therapies
Bild, A., Yao, G., Chang, J. T., Wang, Q., Potti, A., Chasse, D. A. D., Joshi, M.-B., Harpole, D. H., Lancaster, J. M., Berchuck, A., et al. (2005) · Nature · doi:10.1038/nature04296 · Cited by 2,008
BRAF mutation predicts sensitivity to MEK inhibition
Solit, D. B., Garraway, L. A., Pratilas, C. A., Sawai, A., Getz, G. A., Basso, A., Ye, Q., Lobo, J. M., She, Y., Osman, I., et al. (2005) · Nature · doi:10.1038/nature04304 · Cited by 1,326
Self-citationBRAF and RAS mutations in human lung cancer and melanoma.
Brose, M. S., Volpe, P., Feldman, M. D., Kumar, M. S., Rishi, I., Gerrero, R. M., Einhorn, E., Herlyn, M., Minna, J. D., Nicholson, A. G., et al. (2002) · PubMed · Cited by 1,048
Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo
Sebolt, J. S., Dudley, D. T., Herrera, R., Becelaere, K. V., Wiland, A. M., Gowan, R. C., Tecle, H., Barrett, S. D., Bridges, A. J., Przybranowski, S. A., et al. (1999) · Nature Medicine · doi:10.1038/10533 · Cited by 972
Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies
Stommel, J. M., Kimmelman, A. C., Ying, H., Nabioullin, R., Ponugoti, A. H., Wiedemeyer, R., Stegh, A. H., Bradner, J. E., Ligon, K. L., Brennan, C., et al. (2007) · Science · doi:10.1126/science.1142946 · Cited by 938
Cited by
Sorted by citations
Items 101–200 of 278
Integrated molecular and clinical analysis of BRAF-mutant glioma in adults
Schreck, K. C., Langat, P., Bhave, V. M., Li, T., Woodward, E. L., Pratilas, C. A., Eberhart, C. G., & Bi, W. L. (2023) · npj Precision Oncology · doi:10.1038/s41698-023-00359-y · Cited by 38
Self-citationSini, P., Gürtler, U., Zahn, S. K., Baumann, C., Rudolph, D., Baumgartinger, R., Strauss, E., Haslinger, C., Tontsch-Grunt, U., Waizenegger, I. C., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0066 · Cited by 38
Nair, N. U., Das, A., Rogkoti, V.-M., Fokkelman, M., Marcotte, R., de Jong, C. G., Koedoot, E., Lee, J. S., Meilijson, I., Hannenhalli, S. S., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-47440-w · Cited by 37
Cossa, G., Lanzi, C., Cassinelli, G., Carenini, N., Arrighetti, N., Gatti, L., Corna, E., Zunino, F., Zaffaroni, N., & Perego, P. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.02.016 · Cited by 33
Liu, S., Zou, Q., Chen, J., Yao, X., Guan, P., Liang, W., Deng, P., Lai, X., Yin, J., Chen, J., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci145035 · Cited by 33
Lebedev, T. D., Khabusheva, E., Mareeva, S. R., Ivanenko, K. A., Morozov, A. V., Spirin, P., Рубцов, П. М., Snezhkina, A. V., Kudryavtseva, A. V., Sorokin, M., et al. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.102226 · Cited by 34
Soria, J., Fülöp, A., Maciel, C. D., Fischer, J. R., Girotto, G. C., Lago, S., Smit, E. F., Ostoros, G., Eberhardt, W., Lishkovska, P., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx628 · Cited by 33
Self-citationWu, Y., Chen, M., & Qin, Y. (2025) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1012905 · Cited by 42
Melosky, B. L., Bradbury, P. A., Tu, D., Florescu, M., Reiman, T., Nicholas, G. A., Basappa, N. S., Rothenstein, J. M., Goffin, J. R., Laurie, S. A., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.04.027 · Cited by 32
Gupta, A., Towers, C., Willenbrock, F. W., Brant, R., Hodgson, D., Sharpe, A. D., Smith, P. D., Cutts, A., Schuh, A., Asher, R. G., et al. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0673-5 · Cited by 32
Self-citationSeipel, K., Marques, M. T., Sidler, C. L., Mueller, B. U., & Pabst, T. (2018) · Cancers · doi:10.3390/cancers10060170 · Cited by 31
Trinidad, A. G., Whalley, N., Rowlinson, R. A., Delpuech, O., Dudley, P., Rooney, C., & Critchlow, S. E. (2017) · Oncogene · doi:10.1038/onc.2017.224 · Cited by 31
Finn, R. S., Ahn, D. H., Javle, M. M., Tan, B. R., Weekes, C. D., Bendell, J. C., Patnaik, A., Khan, G. N., Laheru, D. A., Chavira, R., et al. (2018) · Investigational New Drugs · doi:10.1007/s10637-018-0600-2 · Cited by 32
Self-citationLiu, D., Liu, X., & Xing, M. (2013) · Cell Cycle · doi:10.4161/cc.26971 · Cited by 31
Uitdehaag, J. C. M., Kooijman, J. J., de Roos, J. A. D. M., Prinsen, M. B. W., Dylus, J., Willemsen‐Seegers, N., Kawase, Y., Sawa, M., de Man, J., van Gerwen, S. J. C., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0877 · Cited by 30
Molecular Pathways: The Basis for Rational Combination Using MEK Inhibitors in KRAS-Mutant Cancers
Okumura, S., & Janne, P. A. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2365 · Cited by 30
Iizuka-Ohashi, M., Watanabe, M., Sukeno, M., Morita, M., Hoang, N. T. H., Kuchimaru, T., Kizaka‐Kondoh, S., Sowa, Y., Sakaguchi, K., Taguchi, T., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.24696 · Cited by 29
Identification of Pharmacodynamic Transcript Biomarkers in Response to FGFR Inhibition by AZD4547
Delpuech, O., Rooney, C., Mooney, L. M., Baker, D., Shaw, R. A., Dymond, M., Wang, D. Y. Q., Zhang, P., Cross, S., Veldman-Jones, M. H., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0297 · Cited by 27
Self-citationClinically Viable Gene Expression Assays with Potential for Predicting Benefit from MEK Inhibitors
Brant, R., Sharpe, A. D., Liptrot, T., Dry, J. R., Harrington, E. A., Barrett, J. C., Whalley, N., Womack, C., Smith, P. D., & Hodgson, D. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0021 · Cited by 29
Self-citationNational Cancer Institute (NCI) state of the science: Targeted radiosensitizers in colorectal cancer
George, T. J., Franke, A. J., Chakravarthy, A. B., Das, P., Dasari, A. N., El‐Rayes, B. F., Hong, T. S., Kinsella, T. J., Landry, J. C., Lee, J. J., et al. (2019) · Cancer · doi:10.1002/cncr.32150 · Cited by 28
Davis, T. B., Yang, M., Schell, M. J., Wang, H., Ma, L., Pledger, W. J., & Yeatman, T. J. (2018) · Scientific Reports · doi:10.1038/s41598-018-27584-x · Cited by 27
Zewdu, R., Mehrabad, E. M., Ingram, K., Fang, P., Gillis, K. L., Camolotto, S. A., Orstad, G., Jones, A. D., Mendoza, M. C., Spike, B. T., et al. (2021) · eLife · doi:10.7554/elife.66788 · Cited by 22
Li, Y., Dong, Q., & Cui, Y. (2019) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2019.0137 · Cited by 25
Flemington, V., Davies, E. J., Robinson, D. M., Sandin, L. C., Delpuech, O., Zhang, P., Hanson, L. L., Farrington, P. M., Bell, S., Falenta, K., et al. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0002 · Cited by 26
Self-citationde Vriendt, V., Roock, W. D., Narzo, A. F. D., Tian, S., Biesmans, B., Jacobs, B., Budínská, E., Sagaert, X., Rossi, S., D’Ario, G., et al. (2013) · Biomarkers · doi:10.3109/1354750x.2013.819038 · Cited by 25
Adaptation of a RAS pathway activation signature from FF to FFPE tissues in colorectal cancer
Omolo, B., Yang, M., Lo, F. Y., Schell, M. J., Austin, S., Howard, K., Madan, A., & Yeatman, T. J. (2016) · BMC Medical Genomics · doi:10.1186/s12920-016-0225-2 · Cited by 25
Yang, M., Davis, T. B., Pflieger, L., Nebozhyn, M. V., Loboda, A., Wang, H., Schell, M. J., Thota, R., Pledger, W. J., & Yeatman, T. J. (2022) · BMC Cancer · doi:10.1186/s12885-022-09344-3 · Cited by 22
“Two gene expression signatures predictive of response/resistance to MEKi have been developed using large cell line panels of diverse tumor types including melanoma, lung and colon as reported by Dry et al.[6].”
BackgroundMethodResultInfluentialSchreck, K. C., Strowd, R. E., III, Nabors, B., Ellingson, B. M., Chang, M., Tan, S. K., Abdullaev, Z., Turakulov, R. I., Aldape, K., Danda, N., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-3241 · Cited by 24
Borcherding, D. C., Amin, N. V., He, K., Zhang, X., Lyu, Y., Dehner, C. A., Bhatia, H., Gothra, A., Daud, L., Ruminski, P., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-3722 · Cited by 24
Self-citationZhu, Y., Tang, S., Yuan, Q., Fu, J., He, J., Liu, Z., Zhao, X., Li, Y., Zhao, Y., Zhang, Y., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101375 · Cited by 23
FoxA1/2-dependent epigenomic reprogramming drives lineage switching in lung adenocarcinoma
Gillis, K., Orellana, W. A., Wilson, E., Parnell, T. J., Fort, G., Fang, P., Dadzie, H. E., Murphy, B., Zhang, X., & Snyder, E. L. (2024) · Developmental Cell · doi:10.1016/j.devcel.2024.10.009 · Cited by 23
Ras–MEK Signaling Mediates a Critical Chk1-Dependent DNA Damage Response in Cancer Cells
Lee, H.-J., Cao, Y., Pham, V. C., Blackwood, E. R., WILSON, C. A., Evangelista, M., Klijn, C. N., Stokoe, D., & Settleman, J. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0504 · Cited by 22
Hyper-active RAS/MAPK introduces cancer-specific mitotic vulnerabilities
Herman, J., Romain, R. R., Hoellerbauer, P., Shirnekhi, H. K., King, D. C., DeLuca, K. F., Nishimura, E. O., Paddison, P. J., & DeLuca, J. G. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2208255119 · Cited by 21
Wei, Y., Han, S., Wen, J., Liao, J., Liang, J., Yu, J., Chen, X., Xiang, S., Huang, Z., & Zhang, B. (2023) · Journal of Biomedical Science · doi:10.1186/s12929-023-00909-3 · Cited by 25
Inhibition of metadherin sensitizes breast cancer cells to AZD6244
Kong, X., Moran, M. S., Zhao, Y., & Yang, Q. (2012) · Cancer Biology & Therapy · doi:10.4161/cbt.13.1.18868 · Cited by 23
KRAS mutant NSCLC, a new opportunity for the synthetic lethality therapeutic approach.
de Castro, J., & Belda-Iniesta, C. (2013) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2013.02.07 · Cited by 22
Zhao, W., Chen, B., Guo, X., Wang, R., Chang, Z., Dong, Y., Song, K., Wang, W., Qi, L., Gu, Y., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7956 · Cited by 22
BRAF and beyond: Tailoring strategies for the individual melanoma patient
Khushalani, N. I., & Jarkowski, A. (2014) · Journal of Carcinogenesis · doi:10.4103/1477-3163.126759 · Cited by 22
Tumor Cell Resistance to the Inhibition of BRAF and MEK1/2
Chen, W., & Park, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914837 · Cited by 21
A new molecular signature method for prediction of driver cancer pathways from transcriptional data
Rykunov, D., Beckmann, N. D., Li, H., Uzilov, A. V., Schadt, E. E., & Reva, B. A. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw269 · Cited by 21
Repurposing EGFR Inhibitor Utility in Colorectal Cancer in Mutant APC and TP53 Subpopulations
Yang, M., Schell, M. J., Loboda, A. P., Nebozhyn, M., Li, J., Teer, J. K., Pledger, W. J., & Yeatman, T. J. (2019) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-18-1383 · Cited by 21
Program, N. C. S., Fufa, T., Baxter, L. L., Wedel, J. C., Gildea, D. E., Loftus, S. K., & Pavan, W. J. (2019) · Epigenetics & Chromatin · doi:10.1186/s13072-019-0297-2 · Cited by 24
Kurian, N., Cohen, T. S., Öberg, L., Zan, E. D., Skogberg, G., Vollmer, S., Baturcam, E., Svanberg, P., Bonn, B., Smith, P. D., et al. (2019) · International Journal of COPD · doi:10.2147/copd.s211619 · Cited by 21
Self-citationEvaluating the consistency of large-scale pharmacogenomic studies
Rahman, R., Dhruba, S. R., Matlock, K., Niz, C. D., Ghosh, S., & Pal, R. (2018) · Briefings in Bioinformatics · doi:10.1093/bib/bby046 · Cited by 18
Identification of transcriptional regulatory networks specific to pilocytic astrocytoma
Deshmukh, H., Yu, J., Shaik, J. S., MacDonald, T. J., Perry, A., Payton, J. E., Gutmann, D. H., Watson, M. A., & Nagarajan, R. (2011) · BMC Medical Genomics · doi:10.1186/1755-8794-4-57 · Cited by 20
Molecular Markers of Response to Treatment for Melanoma
Sznol, M. (2011) · The Cancer Journal · doi:10.1097/ppo.0b013e318212dd5a · Cited by 20
HER3 expression and MEK activation in non-small-cell lung carcinoma
Manickavasagar, T., Yuan, W., Carreira, S., Gürel, B., Miranda, S., Ferreira, A., Crespo, M., Riisnaes, R., Baker, C., O'Brien, M. E. R., et al. (2021) · Lung Cancer Management · doi:10.2217/lmt-2020-0031 · Cited by 20
Song, K., Gao, Q., Zhou, J., Qiu, S., Huang, X., Wang, X., & Fan, J. (2012) · Hepatobiliary & pancreatic diseases international · doi:10.1016/s1499-3872(12)60145-3 · Cited by 19
Gysin, S., Paquette, J., & McMahon, M. (2012) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-12-0188 · Cited by 19
Integrating phenotypic small-molecule profiling and human genetics: the next phase in drug discovery
Johannessen, C. M., Clemons, P. A., & Wagner, B. K. (2014) · Trends in Genetics · doi:10.1016/j.tig.2014.11.002 · Cited by 18
Targeted therapy of obesity-associated colon cancer
Chen, J. (2012) · Translational gastrointestinal cancer · Cited by 18
Targeted agents for the treatment of metastatic melanoma
Dancey, J. E., & Monzon (2012) · OncoTargets and Therapy · doi:10.2147/ott.s21259 · Cited by 18
Combination of BMI1 and MAPK/ERK inhibitors is effective in medulloblastoma
Badodi, S., Pomella, N., Lim, Y. M., Brandner, S., Morrison, G. M., Pollard, S. M., Zhang, X., Zabet, N. R., & Marino, S. (2022) · Neuro-Oncology · doi:10.1093/neuonc/noac052 · Cited by 17
Liu, C., Jiang, J., Gu, J., Yu, Z., Wang, T., & Lu, H. J. (2016) · BMC Systems Biology · doi:10.1186/s12918-016-0358-0 · Cited by 18
Flint, A. C., Mitchell, D. K., Angus, S. P., Smith, A. E., Bessler, W., Jiang, L., Mang, H. E., Li, X., Lu, Q., Rodriguez, B., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2854 · Cited by 17
Chung, E. J., Urick, M. E., Kurshan, N., Shield, W. P., Asano, H., Smith, P. D., SCROGGINS, B. S., Burkeen, J., & Citrin, D. E. (2013) · International Journal of Oncology · doi:10.3892/ijo.2013.1890 · Cited by 16
Self-citationTreatment of KRAS-Mutant Non–Small Cell Lung Cancer
Kaufman, J. M., & Stinchcombe, T. E. (2017) · JAMA · doi:10.1001/jama.2017.3436 · Cited by 16
Impact of between-tissue differences on pan-cancer predictions of drug sensitivity
Lloyd, J. P., Soellner, M. B., Merajver, S. D., & Li, J. Z. (2021) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1008720 · Cited by 15
Pfohl, U., Loskutov, J., Bashir, S., Kühn, R., Herter, P., Templin, M. F., Mamlouk, S., Belanov, S., Linnebacher, M., Bürtin, F., et al. (2022) · Cancers · doi:10.3390/cancers14133252 · Cited by 13
Myszor, I. T., Lapka, K., Hermannsson, K., Rekha, R., Bergman, P., & Gudmundsson, G. H. (2024) · Scientific Reports · doi:10.1038/s41598-024-57251-3 · Cited by 12
Gong, J., Chen, Y., Yang, L., Pillai, R. K., Shirasawa, S., & Fakih, M. (2017) · Anticancer Research · doi:10.21873/anticanres.11634 · Cited by 14
Jimenez, T., Barrios, A., Tucker, A., Collazo, J., Arias, N., Fazel, S., Baker, M., Halim, M., Huynh, T., Singh, R., et al. (2020) · PubMed Central · Cited by 14
eIF4F controls ERK MAPK signaling in melanomas with BRAF and NRAS mutations
Valčíková, B., Vadovičová, N., Smolkova, K., Zacpalova, M., Krejčı́, P., Lee, S., Rauch, J., Kölch, W., von Kriegsheim, A., Dorotikova, A., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2321305121 · Cited by 12
Sherwood, J. L., Müller, S., Orr, M. C. M., Ratcliffe, M., & Walker, J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0100566 · Cited by 13
Ang, J. E., Pál, Á., Asad, Y. J., Henley, A. T., Valenti, M. R., Box, G., Brandon, A. D. H., Revell, V. L., Skene, D. J., Venturi, M., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0881 · Cited by 12
Targeting MEK for the Treatment of Non–Small-Cell Lung Cancer
Goldman, J. W., & Garon, E. B. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31826df0bc · Cited by 12
Opposing lineage specifiers induce a protumor hybrid identity state in lung adenocarcinomaPreprint
Fort, G., Arnold, H., Camolotto, S. A., O’Toole, K. T., Tariq, R., Waters, A. K., Gillis, K., & Snyder, E. L. (2025) · Genes & Development · doi:10.1101/gad.352742.125 · Cited by 13
PTPRS drives adaptive resistance to MEK/ERK inhibitors through SRC
Davis, T. B., Yang, M., Wang, H., Lee, C., Yeatman, T. J., & Pledger, W. J. (2019) · Oncotarget · doi:10.18632/oncotarget.27335 · Cited by 11
Vis, D. J., Jaaks, P., Aben, N., Coker, E. A., Barthorpe, S., Beck, A., Hall, C., Hall, J. A. M., Lightfoot, H. W., Lleshi, E., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101687 · Cited by 11
McNew, K. L., Whipple, W. J., Mehta, A. K., Grant, T. J., Ray, L. C., Kenny, C. J., & Singh, A. (2016) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-16-0173 · Cited by 12
Chesnokov, M., Yadav, A., & Chefetz, I. (2022) · bioRxiv · doi:10.3390/ijms232113365 · Cited by 7
Management of KRAS-Mutant Non-Small Cell Lung Cancer in the Era of Precision Medicine
Aredo, J. V., & Padda, S. K. (2018) · Current Treatment Options in Oncology · doi:10.1007/s11864-018-0557-6 · Cited by 12
Wang, F., Wanggou, S., Cao, H., Jiang, N., Yang, Q., Huang, Q., Huang, C., & Li, X. (2020) · 癌症：英文版 · doi:10.1002/cac2.12092 · Cited by 11
Correlation between MEK signature and Ras gene alteration in advanced gastric cancer
Ahn, S., Brant, R., Sharpe, A. D., Dry, J. R., Hodgson, D., Kilgour, E., Kim, K., Kim, S. T., Park, S. H., Kang, W. K., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.18182 · Cited by 10
Self-citationInduction of immunoglobulin transcription factor 2 and resistance to MEK inhibitor in melanoma cells
Hur, E., Goo, B.-K., Moon, J., Choi, Y., Hwang, J. J., Kim, C., Bae, K., Choi, J., Cho, S. Y., Yang, S., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17866 · Cited by 10
Shrestha, G., MacNeil, S. M., McQuerry, J. A., Jenkins, D. F., Sharma, S., & Bild, A. H. (2016) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2016.06.012 · Cited by 10
Novo, S. M., Wedge, S. R., & Stark, L. A. (2017) · Scientific Reports · doi:10.1038/s41598-017-12222-9 · Cited by 12
Osum, S. H., Coutts, A. W., Duerre, D. J., Tschida, B. R., Kirstein, M. N., Fisher, J. E., Bell, W. R., Delpuech, O., Smith, P. D., Widemann, B. C., et al. (2021) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdab020 · Cited by 9
Self-citationOno, H., Horinaka, M., Sukeno, M., Morita, M., Yasuda, S., Nishimoto, E., Konishi, E., & Sakai, T. (2021) · Cancer Science · doi:10.1111/cas.15071 · Cited by 9
Boers‐Sonderen, M. J., Desar, I. M. E., Blokx, W. A. M., Timmer-Bonte, J. N. H., & van Herpen, C. M. (2012) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e328350737d · Cited by 9
Cx43 enhances response to BRAF/MEK inhibitors by reducing DNA repair capacity
Varela-Vázquez, A., Guitián‐Caamaño, A., Carpintero-Fernández, P., Carneiro-Figueira, A., Álvarez, V., Varela-Eirín, M., Calleja-Chuclá, T., Bravo, S. B., Vidal, A., Sendón-Lago, J., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-60971-3 · Cited by 11
Church, C., Fay, C., Kriukov, E., Liu, H., Cannon, A. D., Baldwin, L. A., Crossman, D. K., Korf, B. R., Wallace, M. R., Gross, A. M., et al. (2024) · Acta Neuropathologica Communications · doi:10.1186/s40478-024-01821-z · Cited by 8
A Meta-Analysis Approach for Characterizing Pan-Cancer Mechanisms of Drug Sensitivity in Cell Lines
Wang, K., Shrestha, R., Wyatt, A. W., Reddy, A., Lehár, J., Wang, Y., Lapuk, A. V., & Collins, C. C. (2014) · PLoS ONE · doi:10.1371/journal.pone.0103050 · Cited by 8
BDKANN - Biological Domain Knowledge-based Artificial Neural Network for drug response predictionPreprint
Snow, O., Sharifi-Noghabi, H., Lu, J., Zolotareva, O. I., Lee, M., & Ester, M. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/840553 · Cited by 8
Ascierto, P. A., Tang, H., Dolfi, S. C., Nyakas, M., Svane, I. M., Muñoz‐Couselo, E., Grob, J., Gomez‐Roca, C., Chiarion‐Sileni, V., Peltola, K. J., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-009773 · Cited by 7
Allosteric MEK1/2 Inhibitors for the Treatment of Cancer: an Overview
Mcdermott, L. (2015) · Journal of Drug Research and Development · doi:10.16966/2470-1009.101 · Cited by 7
Bosotti, R., Carpinelli, P., Healy, S., Locatelli, G., Cappella, P., Lanfrancone, L., Calogero, R., Moll, J. K., & Isacchi, A. (2011) · Gene · doi:10.1016/j.gene.2011.08.014 · Cited by 7
Belmont, P. J., Budínská, E., Jiang, P., Sinnamon, M. J., Coffee, E. M., Roper, J., Xie, T., Rejto, P. A., Derkits, S., Sansom, O. J., et al. (2014) · Disease Models & Mechanisms · doi:10.1242/dmm.013904 · Cited by 7
Ayanlaja, A. A., Chang, M., Lalwani, K., Ioannou, M., Wang, J., Jagtap, S., Yang, Y., Lucas, C. G., Levy, J. M. M., Gartrell, R. D., et al. (2025) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdaf170 · Cited by 7
Self-citationPan, S., Mirchia, K., Payne, E., Liu, S. J., Al-Adli, N. N., Peeran, Z., Shukla, P. D., Young, J. S., Gupta, R. K., Wu, J., et al. (2025) · JCI Insight · doi:10.1172/jci.insight.192658 · Cited by 6
Leukemic stem cell subtypes determine venetoclax resistance and therapeutic vulnerabilities in AML
Waclawiczek, A., Leppä, A., Renders, S., Bergerweiss, I., Stumpf, K., Betz, B., Gabrowski, S., Huang, F. Y., Lalioti, M., Hempel, B., et al. (2026) · Cell stem cell · doi:10.1016/j.stem.2026.04.012 · Cited by 9
Kim, S. W., Kim, H. K., Lee, J. I., Jang, H. W., Choe, J., Kim, J., Kim, J. S., Hur, K. Y., Kim, J. H., & Chung, J. H. (2013) · Endocrine Research · doi:10.3109/07435800.2012.723292 · Cited by 6
Escape from G1 arrest during acute MEK inhibition drives the acquisition of drug resistance
Channathodiyil, P., May, K., Segonds-Pichon, A., Smith, P. D., Cook, S. J., & Houseley, J. M. (2022) · NAR Cancer · doi:10.1093/narcan/zcac032 · Cited by 6
Self-citationLow-grade serous carcinoma: molecular features and contemporary treatment strategies
Angarita, A. M., Cholakian, D., & Fader, A. N. (2015) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2015.1052411 · Cited by 6
Sahoo, S., Suvarna, S., Chandra, A., Wahi, S., Kumar, P., & Khanna, G. (2013) · PubMed · Cited by 6
Ogino, A., Vajdi, A., Mu, X. J., Mahadevan, N. R., Ngo, K. H., Booker, M. A., Cejas, P., Okoro, J. J., Xu, M., Springer, B. F., et al. (2026) · JCI Insight · doi:10.1172/jci.insight.197008 · Cited by 5
Expanding targeted therapy to NRAS-mutated melanoma.
Gibney, G., & Weber, J. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70054-8 · Cited by 4
Chuang, J., Gong, J., Li, S. M., Wang, C., & Fakih, M. (2022) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2022.05.004 · Cited by 6
Targeting the Mitogen-Activated Protein Kinase Pathway in Low-Grade Serous Carcinoma of the Ovary
McLachlan, J., Gore, M. E., & Banerjee, S. N. (2016) · Pharmacogenomics · doi:10.2217/pgs.16.24 · Cited by 5
Gamo, K., Okuzono, Y., Yabuki, M., Ochi, T., Sugimura, K., Sato, Y., Sagara, M., Hayashi, H., Ishimura, Y., Nishimoto, Y., et al. (2018) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izy079 · Cited by 5
Metadata
- Authors
- Dry, J. R., Pavey, S., Pratilas, C. A., Harbron, C., Runswick, S., Hodgson, D., Chresta, C., McCormack, R., Byrne, N., Cockerill, M., Graham, A., Beran, G., Cassidy, A., Haggerty, C., Brown, H., Ellison, G., Dering, J., Taylor, B. S., Stark, M., Bonazzi, V., Ravishankar, S., Packer, L., Xing, F., Solit, D. B., Finn, R. S., Rosen, N., Hayward, N. K., French, T., & Smith, P. D.
- Affiliations
- AstraZeneca (United Kingdom) (GB)
- Corresponding author
- Dry, Jonathan R.
- ORCID
- Venue
- Cancer Research
- Published
- 2010-03-14
- Volume
- 70
- Issue
- 6
- Pages
- 2264-2273
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- PMC
- PMC3166660
- OpenAlex
- W2128445526
- Cited by
- 262
- References
- 46
- Citations by year
- 2026: 7 · 2025: 11 · 2024: 11 · 2023: 23 · 2022: 13 · 2021: 11 · 2020: 11 · 2019: 17 · 2018: 16 · 2017: 22 · 2016: 17 · 2015: 14 · 2014: 16 · 2013: 23 · 2012: 23
- FWCI
- 9.50
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (K08CA127350)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Keywords
- selumetinib, MEK inhibitors, drug resistance, gene expression signatures, phosphatidylinositol 3-kinase, melanoma, cancer cell lines, xenograft models, predictive biomarkers, targeted therapy
- MeSH terms
- Benzimidazoles, Humans, Neoplasms, Phosphatidylinositol 3-Kinases, Reverse Transcriptase Polymerase Chain Reaction, Gene Expression Profiling, MAP Kinase Kinase Kinases, MAP Kinase Signaling System, Cell Line, Tumor, Proto-Oncogene Proteins B-raf, Proto-Oncogene Proteins c-akt, PTEN Phosphohydrolase
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
